186 related articles for article (PubMed ID: 21244767)
21. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
Botzoris V; Drosos AA
Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379
[TBL] [Abstract][Full Text] [Related]
22. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis.
Bellisai F; Morozzi G; Scaccia F; Chellini F; Simpatico A; Pecetti G; Galeazzi M
Int J Immunopathol Pharmacol; 2011; 24(1):261-4. PubMed ID: 21496413
[TBL] [Abstract][Full Text] [Related]
24. Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A; Walker KM; Pope JE;
Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
[TBL] [Abstract][Full Text] [Related]
25. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
Roman Ivorra JA; Simeon CP; Alegre Sancho JJ; Egurbide MV; Castillo MJ; Lloria X; Fonollosa V
J Rheumatol; 2011 Aug; 38(8):1631-5. PubMed ID: 21632679
[TBL] [Abstract][Full Text] [Related]
26. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
Ahmadi-Simab K; Lamprecht P; Hellmisch B; Gross WL
Z Rheumatol; 2004 Dec; 63(6):495-7. PubMed ID: 15605216
[No Abstract] [Full Text] [Related]
28. Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.
Yagi S; Akaike M; Iwase T; Kusunose K; Niki T; Yamaguchi K; Koshiba K; Yoshida S; Sumitomo-Ueda Y; Aihara K; Hirata Y; Dagvasumberel M; Taketani Y; Tomita N; Yamada H; Soeki T; Wakatsuki T; Matsumoto T; Sata M
Intern Med; 2010; 49(21):2309-12. PubMed ID: 21048365
[TBL] [Abstract][Full Text] [Related]
29. [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].
Riemekasten G; Beissert S; Distler JH; Kreuter A; Müller-Ladner U
Z Rheumatol; 2017 Apr; 76(3):228-237. PubMed ID: 27535277
[TBL] [Abstract][Full Text] [Related]
30. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.
Jain M; Varga J
Expert Opin Pharmacother; 2006 Aug; 7(11):1487-501. PubMed ID: 16859432
[TBL] [Abstract][Full Text] [Related]
31. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
Trombetta AC; Pizzorni C; Ruaro B; Paolino S; Sulli A; Smith V; Cutolo M
J Rheumatol; 2016 Nov; 43(11):2033-2041. PubMed ID: 27744392
[TBL] [Abstract][Full Text] [Related]
32. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
[TBL] [Abstract][Full Text] [Related]
33. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
34. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
Varga J
Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045
[No Abstract] [Full Text] [Related]
35. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
36. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
37. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis.
Cutolo M; Ruaro B; Pizzorni C; Ravera F; Smith V; Zampogna G; Paolino S; Seriolo B; Cimmino M; Sulli A
J Rheumatol; 2014 May; 41(5):881-6. PubMed ID: 24692525
[TBL] [Abstract][Full Text] [Related]
38. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
Sharma S; Kashour T; Philipp R
Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
Ramos-Casals M; Brito-Zerón P; Nardi N; Claver G; Risco G; Parraga FD; Fernandez S; Julià M; Font J
Rheumatology (Oxford); 2004 Nov; 43(11):1454-6. PubMed ID: 15502001
[No Abstract] [Full Text] [Related]
40. [Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)].
Riccardi MT; Chialà A; Lannone F; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2007; 59(2):135-9. PubMed ID: 17603693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
